RecruitingNot ApplicableNCT02986516

Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease

Title of Study: SAcral Chordoma: a Randomized & Observational Study on Surgery Versus Definitive Radiation Therapy in Primary Localized Disease (SACRO)


Sponsor

Italian Sarcoma Group

Enrollment

100 participants

Start Date

Mar 16, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria8

  • Histologically confirmed diagnosis (brachyury expression) of primary sacral chordoma,of any diameter and arising at any site from S1 to coccyx.
  • Age≥18years
  • ECOG-performance status (PS) 0-2
  • No previous antineoplastic therapy
  • Macroscopic tumor detectable at MRI/CT scan
  • Patient amenable for surgery
  • Patient amenable for RT
  • Written informed consent given before the enrolment, according to International Conference on Harmonisation/good clinical practice (ICH/GCP).

Exclusion Criteria16

  • Distant metastasis
  • Inability to maintain treatment position
  • Prior radiotherapy to the pelvic region
  • Prior therapy for sacral chordoma (including surgery, cryoablation, hyperthermia, etc)
  • Local conditions that increase the risk of RT toxicity (tumor ulcerated skin infiltration, non-healing soft tissue infection, fistula in treatment field)
  • Rectal wall infiltration
  • General conditions that increase the risk of RT toxicity (active sclerodermia, xeroderma pigmentosum, cutaneous porphyria)
  • Presence of a second active cancer (with the exception of non-melanoma skin cancer in-situ cervix neoplasia and other in-situ neoplasia)
  • Severe comorbidities resulting in a prognosis of less than 6 months
  • Inability to give informed consent
  • Other malignancy within the last 5 years
  • Performance status ≥ 2 (ECOG).
  • Significant cardiovascular disease (for example, dyspnea > 2 NYHA)
  • Significant systemic diseases grade >3 on the NCI-CTCAE v4.03 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity
  • Women who are pregnant or breast-feeding
  • Psychological, familial, social or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRandomized Cohort

Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization

RADIATIONProspective cohort

Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated


Locations(28)

Medical University of Graz

Graz, Austria

EBG GmbH MedAustron

Wiener Neustadt, Österreich, Austria

Medical Faculty Carl Gustav Carus Faculty of Medicine, Department of Radiation Oncology,

Dresden, Germany

University Hospital Carl Gustav Carus Dresden

Dresden, Germany

University Hospital Essen. West German Proton Therapy Center Essen

Essen, Germany

Heidelberg Ion-Beam Therapy Center - HIT

Heidelberg, Germany

National Center for Spinal Disorders

Budapest, Hungary

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, MI, Italy

Istituto Ortopedico Rizzoli

Bologna, Italy

Azienda Ospedaliero-Universitaria Careggi

Florence, Italy

Istituto Clinico Humanitas

Milan, Italy

I.R.C.C.S. Istituto Ortopedico Galeazzi

Milan, Italy

Centro Nazionale di Adroterapia Oncologica - CNAO

Pavia, Italy

II Clinica Universitaria Ortopedia e Traumatologia AO Pisa

Pisa, Italy

Istituto Regina Elena - IFO

Rome, Italy

Agenzia Provinciale per la Protonterapia - AtreP

Trento, Italy

Saitama Medical Center

Saitama, Japan

Netherlands Cancer Institute

Amsterdam, Netherlands

Leiden University Medical Center

Leiden, Netherlands

Norwegian Radium Hospital/Oslo Univeristi Hospital

Oslo, Norway

Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie

Warsaw, Poland

H. Val D'Hebron

Barcelona, Spain

Hosptial San Pau

Barcelona, Spain

H. San Carlos

Madrid, Spain

Hospital Universitario Virgen del Rocío

Seville, Spain

Hospital Universitario Doctor Peset

Valencia, Spain

The Royal Orthopaedic Hospital

Birmingham, United Kingdom

Royal National Orthopaedic Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02986516


Related Trials